Status:
COMPLETED
Diagnostic Platform to Perform Centralized and Standardized Rapid Molecular Diagnosis by Next Generation Sequencing (NGS) in Patients Diagnosed With Acute Myeloid Leukemia.
Lead Sponsor:
PETHEMA Foundation
Conditions:
Acute Myeloid Leukemia
Eligibility:
All Genders
18+ years
Brief Summary
NGS studies will be done in stem cell leukemic population. The analysis of the samples to the diagnosis will be carried out using the 26 consensus genes: ASXL1 had, CBL, CEBPA, DNMT3A, EZH2, FLT3, GAT...
Detailed Description
All patients diagnosed with AML (new diagnosis or relapsed/refractory disease) can be included. This project aims to establish a platform for comprehensive diagnostic and research platform in the con...
Eligibility Criteria
Inclusion
- All adult patients (≥18 years) with AML (excluding APL) according to the WHO criteria (2008), regardless of the treatment administered by their treating physician.
- Patient has to sign the informed consent form, allowing for sampling, analyses and reporting of the mutational results.
- AML at diagnosis and at relapse or refractoriness.
Exclusion
- Genetic diagnosis of acute promyelocytic leukemia
- No Informed Consent Form
Key Trial Info
Start Date :
October 6 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 15 2019
Estimated Enrollment :
900 Patients enrolled
Trial Details
Trial ID
NCT03311815
Start Date
October 6 2017
End Date
October 15 2019
Last Update
February 16 2021
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Reina Sofía
Córdoba, Spain
2
Hospital Dr. Negrín
Las Palmas de Gran Canaria, Spain
3
Hospital 12 de Octubre
Madrid, Spain
4
Clínica Universidad de Navarra
Pamplona, Spain